• Jyong Biotech posted a net loss of US $4.67 million, widening from US $3.02 million a year earlier.
• Operating loss widened to US $2.61 million as total operating expenses rose 27% to US $2.61 million.
• General and administrative costs climbed 61% to US $1.75 million, while research and development expense fell 12% to US $813,000.
• Interest expense more than doubled to US $2.54 million, while interest income rose to US $610,000 from US $7,000.
• Botreso API-2 CMC package was initially submitted to the U.S. FDA in October 2024, with updated Module 3 and stability data slated for submission in Q2 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jyong Biotech Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-057073), on May 15, 2026, and is solely responsible for the information contained therein.